Feature

Drug pricing does not inspire Americans’ trust


 

Most Americans trust pharmaceutical companies to develop new drugs and share information about side effects and efficacy, but that confidence does not extend to the pricing of drugs, according to a recent survey from the Kaiser Family Foundation.

Survey: Drug pricing brings out consumers' distrust

Only 25% of the respondents said that they currently trust drug companies “a lot” (3%) or “somewhat” (22%) when it comes to pricing their products fairly, which “is a significant decrease from 41% who said they trusted pharmaceutical companies to price their products fairly back in 2008,” Kaiser said in a recent Health Tracking Poll.

Safety issues were also a bit of a sore point in the current survey: Less than half of the 1,440 adults responding said that they trusted pharmaceutical companies a lot (10%) or somewhat (37%) regarding informing the public quickly when a safety concern is discovered.

Trust was more forthcoming when people were asked about the development of new, effective drugs – 71% expressed a favorable opinion – and companies’ offering “reliable information about side effects and safety of drugs,” which received a favorable response from 65% of those surveyed during Feb. 14 to Feb. 24, 2019.

A majority of respondents (61%) also thought that pharmaceutical companies could be trusted to “offer reliable information about how well their drugs work,” the report’s authors noted.

The lack of trust expressed regarding drug pricing also may explain why most consumers (80%) said that drug company profits were a major contributor to the cost of prescription drugs. The cost of research and development, at 69%, was the next most commonly mentioned factor, followed by profits made by pharmacy benefit managers at 63%, according to the report.

Recommended Reading

Health spending: Boomers will spike costs, but growing uninsured will soften their impact
MDedge Cardiology
Lawsuit against ABIM draws $200,000 in donation support
MDedge Cardiology
Final ‘Vision’ report addresses MOC woes
MDedge Cardiology
Physician PAC dollars support candidates against gun regulation
MDedge Cardiology
Talk about déjà vu: Senators set to re-enact drug price hearing of 60 years ago
MDedge Cardiology
What does 'Medicare for all' mean?
MDedge Cardiology
Big pharma says it can’t drop drug list prices alone
MDedge Cardiology
Malpractice suits are less frequent – but more costly
MDedge Cardiology
Workers’ compensation law
MDedge Cardiology
Who is in charge here?
MDedge Cardiology